Eisai Co Ltd is a specialty and generic drug manufacturing company... Show more
The 50-day moving average for ESALF moved above the 200-day moving average on August 21, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 47 cases where ESALF's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on September 03, 2025. You may want to consider a long position or call options on ESALF as a result. In of 61 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ESALF just turned positive on September 08, 2025. Looking at past instances where ESALF's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
ESALF moved above its 50-day moving average on September 03, 2025 date and that indicates a change from a downward trend to an upward trend.
ESALF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 102 cases where ESALF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for ESALF moved out of overbought territory on August 26, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.641) is normal, around the industry mean (17.169). P/E Ratio (29.427) is within average values for comparable stocks, (74.138). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.888). Dividend Yield (0.033) settles around the average of (0.030) among similar stocks. P/S Ratio (1.731) is also within normal values, averaging (46.994).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ESALF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ESALF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Industry PharmaceuticalsGeneric
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
CDL | 68.62 | 0.30 | +0.43% |
VictoryShares US LgCp Hi Div Vol Wtd ETF | |||
ICF | 60.79 | -0.11 | -0.18% |
iShares Select U.S. REIT ETF | |||
EMDM | 27.86 | -0.08 | -0.29% |
First Trust Bloomberg Emr Mkt Dem ETF | |||
ASMH | 58.52 | -0.17 | -0.29% |
ASML HOLDING NV ADRHEDGED ASMH | |||
EVX | 38.40 | -0.19 | -0.49% |
VanEck Environmental Svcs ETF |
A.I.dvisor tells us that ESALF and ESAIY have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESALF and ESAIY's prices will move in lockstep.
Ticker / NAME | Correlation To ESALF | 1D Price Change % | ||
---|---|---|---|---|
ESALF | 100% | N/A | ||
ESAIY - ESALF | 26% Poorly correlated | -1.70% | ||
DVAX - ESALF | 23% Poorly correlated | -1.29% | ||
KHTRF - ESALF | 22% Poorly correlated | +0.13% | ||
SHPH - ESALF | 22% Poorly correlated | +21.79% | ||
BLMH - ESALF | 21% Poorly correlated | -0.89% | ||
More |
Ticker / NAME | Correlation To ESALF | 1D Price Change % |
---|---|---|
ESALF | 100% | N/A |
Pharmaceuticals: Generic industry (221 stocks) | -1% Poorly correlated | +0.51% |